

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Alpha Synergy Development, Inc.	10/15/2012
RECEIVING PARTY DATA	
Name:	Eye Therapies LLC
Street Address:	26933 Camino De Estrella
Internal Address:	2nd Floor
City:	Dana Point
State/Country:	CALIFORNIA
Postal Code:	92624
PROPERTY NUMBERS Total: 19	
Property Type	Number
Application Number:	12460942
Application Number:	12798929
Application Number:	12800942
Application Number:	13066368
Application Number:	12460969
Application Number:	12460968
Application Number:	12460967
Application Number:	13066370
Application Number:	13406321
Application Number:	12460491
Application Number:	12928749
Application Number:	13458559
Patent Number:	8283350
Patent Number:	8080550

CH \$760.00 12460942

PCT Number:	US2009051857
PCT Number:	US2012033452
PCT Number:	US2012033461
PCT Number:	US2010060960
PCT Number:	US2010060944

CORRESPONDENCE DATA

Fax Number: 3128762020

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (312) 876-1800

Email: adiaz@woodphillips.com

Correspondent Name: Wood, Phillips, Katz, Clark & Mortimer

Address Line 1: 500 West Madison Street

Address Line 2: Suite 1130

Address Line 4: Chicago, ILLINOIS 60661

ATTORNEY DOCKET NUMBER:	ASD10554P
-------------------------	-----------

NAME OF SUBMITTER:	Mark Polyakov
--------------------	---------------

Total Attachments: 4
source=2Eye#page1.tif
source=2Eye#page2.tif
source=2Eye#page3.tif
source=2Eye#page4.tif

PATENT ASSIGNMENT AGREEMENT

THIS AGREEMENT is made and entered into as of this October 15, 2012

BY AND BETWEEN:

Alpha Synergy Development, Inc.
26933 Camino De Estrella, 2nd Floor,
Dana Point, CA 92624

AND

Eye Therapies LLC
26933 Camino De Estrella, 2nd Floor,
Dana Point, CA 92624

WITNESSETH

WHEREAS, Assignor and Assignee have entered into a Contribution Agreement dated effective as of October 15, 2012 pursuant to which Assignee acquired from the Assignor the rights, titles and interests in, to and under certain patents and patent applications listed in Schedule A (the "Patents");

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Assignor hereby sells, transfers and assigns to Assignee, its successors and assigns, Assignor's entire rights, titles and interests in, to and under the (i) Patents, (ii) any corresponding patent applications and foreign patent applications including, without limitation, continuation applications, continuation-in-part applications and divisional applications, and any patents which may issue therefore and any patents which may be reissued, re-examined or extended therefrom, and (iii) all rights to sue and recover from third parties damages for past infringements. The foregoing to be held by Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had not this transfer and assignment been made.

IN WITNESS WHEREOF, this Agreement is executed by duly authorized officers at the date previously mentioned.


[The remainder of this page is intentionally left blank. The next page is the signature page.]

ASSIGNOR:


ALPHA SYNERGY DEVELOPMENT, INC.

By its authorized signatory:

Witness: _____



By: _____



Name: James W. McCollum


Title: Chief Executive Officer

ASSIGNEE:


EYE THERAPIES LLC

By its authorized signatory:

Witness: _____



By: _____



Name: Lee Nordan

Title: President

(End of signatures)

[SIGNATURES PAGE TO PATENT ASSIGNMENT AGREEMENT BETWEEN ALPHA
SYNERGY DEVELOPMENT, INC. AND EYE THERAPIES LLC]

Schedule A

Patent Application No. : Patent No.	Country	Title
PCT/US09/51857	US	Vasoconstriction Compositions and Methods of Use
12/460,942	US	Compositions and Methods for Reversing Rebound Hyperemia
12/460,970 : 8,283,350	US	Compositions and Methods for Reducing Capillary Permeability
12/798,929	US	Compositions and Methods for Treatment of Diseases and Conditions with Increased Vascular Permeability
12/800,942	US	Compositions and Methods for Treatment of Diseases and Conditions Associated with Vasodilation and/or Vascular Leakage
PCT/US12/33452	US	Compositions and Methods for Treatment of Pulmonary Diseases and Conditions
13/066,368	US	Compositions and Method for Treatment of Pulmonary Diseases and Conditions
12/460,969	US	Compositions and Methods for Treating Allergic Response
12/460,968	US	Compositions and Methods for Reducing Activation of Alpha-1 Receptors
12/460,967	US	Vasoconstriction Compositions and Methods of Use
PCT/US12/33461	US	Compositions and Methods for the Treatment of Nasal Conditions
13/066,370	US	Compositions and Methods for the Treatment of Nasal Conditions
13/406,321	US	Nasal Compositions and Uses Thereof
12/460,491	US	Preferential Vasoconstriction Compositions and Methods of Use
PCT/US10/60960	US	Compositions and Methods for Ophthalmic Delivery of Nasal Decongestants
PCT/US10/60944	US	Compositions and Methods for Eye Whitening
12/928,749	US	Compositions and Methods for Eye Whitening
13/458,559	US	Compositions and Methods for Improving Night Vision
12/460,954: 8,080,550	US	Anesthetic Compositions and Methods of Use
09803445.7	EP	Vasoconstriction
10838277.1	EP	Compositions and Methods for Ophthalmic Delivery of Nasal Decongestants

Schedule A

2,732,521	CA	Vasoconstriction Compositions and Methods of Use
2,782,872	CA	Compositions and Methods for Ophthalmic Delivery of Nasal Decongestants
2,782,817	CA	Compositions and Methods for Eye Whitening
2011-521223	JP	Vasoconstriction Compositions and Methods of Use
10-2012-7018730	KR	Compositions and Methods for Eye Whitening